Treating VVA: Objective and Subjective Measure of Benefit


Approved treatments of menopause-related symptoms can have narrow indications, but they may offer broader relief of the most bothersome menopause symptoms.

Drug therapies for symptoms related to genituourinary syndrome of menopause (GSM) tend to have narrow indications of use. Ospemifene, for example, has been approved for the treatment of dyspareunia, or painful sex, in postmenopausal women. But new research shows that it may have additional benefits as well.

In this video, David Portman, MD, of the Columbus Center for Women's Health Research, Columbus, Ohio, discusses the research, which shows that ospemifene is associated not only with improvements in symptoms of dyspareunia but also with improvements of a woman's "most bothersome" symptom of menopause, whatever she defines that to be.

This research was presented in October 2014 at the 25th Annual Meeting of The North American Menopause Society.

Related Videos
Why doxycycline PEP lacks clinical data for STI prevention in women
Understanding the impact of STIs on young adults | Image Credit:
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit:
How to address sexual dysfunction during menopause | Image Credit:
Hot flashes poorly impact sleep quality | Image Credit:
What's new in endometrium care? | Image Credit:
How to manage bone health in midlife women | Image Credit: -
Mary Jane Minkin, MD, discusses The Menopause Society 2023 Annual Meeting | Image Credit: Yale School of Medicine
Highlights from The Menopause Society 2023 Annual Meeting  | Image Credit:
How fezolinetant changes management of hot flashes | Image Credit:
Related Content
© 2024 MJH Life Sciences

All rights reserved.